EICHOR
● Terminated
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: Gilead Sciences
About this study
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (88)
| Ironwood Cancer and Research Center | Chandler, Arizona, United States | — |
| City of Hope | Duarte, California, United States | — |
| UCLA Hematology/Oncology | Los Angeles, California, United States | — |
| Stanford Cancer Institute | Palo Alto, California, United States | — |
| Torrance Memorial Physician Network - Cancer Care Associates | Redondo Beach, California, United States | — |
| Providence Medical Foundation | Santa Rosa, California, United States | — |
| Memorial Healthcare System | Hollywood, Florida, United States | — |
| Ocala Oncology Center | Ocala, Florida, United States | — |
| University Center and Blood Center,LLC. | Athens, Georgia, United States | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis, Indiana, United States | — |
| Virginia Piper Cancer Center (Alliant Health | Minneapolis, Minnesota, United States | — |
| Washington University of Medicine- Siteman Cancer Center | St Louis, Missouri, United States | — |
+ 76 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04854499